Adam's Take Adam's Take November 14, 2024 STAT Plus: Neurogene and the race to the bottom of gene therapy
Adam's Take Adam's Take November 7, 2024 STAT Plus: Biotech and Donald Trump: A conversation about what comes next
Adam's Take Adam's Take October 31, 2024 STAT Plus: Capricor and the FDA: A daring, risky filing strategy
Adam's Take Adam's Take October 24, 2024 STAT Plus: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line